As per attachment
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eiko Lifesciences' board approved several key changes at its July 29, 2025 meeting. Whole Time Director Mr. Umesh More resigned with immediate effect due to other business commitments, and Mr. Sumukh Prabhakar Vartak (21+ years of experience in Active Pharmaceutical Ingredients) was appointed as additional Whole Time Director for a 5-year term. The board also approved re-appointments of two Independent Directors — Ms. Kajal Kothari (5 years from Sep 9, 2025) and Mr. Rajkumar Baheti (5 years from Feb 10, 2026). Additionally, the board increased the authorized share capital from Rs. 14 crore to Rs. 20 crore (to 2 crore equity shares of Rs. 10 each), signalling potential future fundraising plans. Q1 FY26 standalone results showed revenue from operations at Rs. 745.23 lakhs (down from Rs. 1,075.04 lakhs YoY) but profit after tax nearly doubled to Rs. 69.22 lakhs (EPS of Rs. 0.50 vs Rs. 0.27 YoY). Consolidated PAT tripled to Rs. 111.74 lakhs. The 48th AGM is scheduled for September 5, 2025.
The seamless Whole Time Director transition avoids leadership vacuum, while the doubled Q1 profit (despite lower revenue) indicates improved margins. The authorized capital hike suggests the company may plan a future equity raise or stock split, which shareholders should watch.